Excited to share our latest publication in #EndocrinePractice (IF 4.2), the flagship journal of the American Association of Clinical Endocrinology #AACE, titled “Effect of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure in patients with type-2 diabetes and hypertension: an updated meta-analysis.” Link: https://lnkd.in/d64ZnQwU This updated #metaanalysis evaluated the potential benefits of sodium-glucose cotransporter 2 (#SGLT2) inhibitors in regulating blood pressure in patients with #type2diabetes and #hypertension. This meta-analysis of ten #RCTs concluded that SGLT2 inhibitors significantly reduce 24-hour ambulatory systolic blood pressure (WMD = -5.08 mmHg, 95% CI: -7.02 to -3.14, p <0.00001) as well as diastolic blood pressure (WMD = -2.73 mmHg, 95% CI: -4.25 to –1.20, p = 0.0005). Our findings recommend that SGLT2 inhibitors may be considered an effective treatment option for lowering blood pressure in addition to standard care in hypertensive patients with type 2 diabetes mellitus. #medicalresearch #scientificpublication #earlycareerresearchers #healthcareinnovation
Bht bht Mubarak ho 👍
Amazing!
Congratulations 🙌
Congratulations Dr. Amber!
Psychiatrist | Fellow | Child and Adolescent Psychiatry |
7moCongratulation